Trexquant Investment LP acquired a new position in shares of Solid Biosciences Inc (NASDAQ:SLDB) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 7,235 shares of the company’s stock, valued at approximately $341,000.
Several other institutional investors also recently bought and sold shares of the company. FMR LLC increased its holdings in Solid Biosciences by 424.4% in the third quarter. FMR LLC now owns 317,997 shares of the company’s stock valued at $15,003,000 after buying an additional 257,354 shares in the last quarter. American International Group Inc. grew its position in shares of Solid Biosciences by 36.3% in the third quarter. American International Group Inc. now owns 8,085 shares of the company’s stock valued at $381,000 after purchasing an additional 2,154 shares during the last quarter. BlackRock Inc. grew its position in shares of Solid Biosciences by 30.6% in the third quarter. BlackRock Inc. now owns 778,249 shares of the company’s stock valued at $36,718,000 after purchasing an additional 182,315 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Solid Biosciences by 31.0% in the third quarter. Bank of New York Mellon Corp now owns 41,778 shares of the company’s stock valued at $1,971,000 after purchasing an additional 9,889 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in shares of Solid Biosciences in the third quarter valued at approximately $24,288,000. 63.59% of the stock is currently owned by institutional investors and hedge funds.
In related news, COO Pedro Alvaro Amorrortu sold 9,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $30.83, for a total transaction of $277,470.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jorge Armando Quiroz sold 40,150 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $31.21, for a total transaction of $1,253,081.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 130,240 shares of company stock worth $4,033,763.
Several research firms have recently commented on SLDB. Citigroup increased their price target on shares of Solid Biosciences from $25.00 to $31.00 and gave the company a “sell” rating in a research report on Monday, December 3rd. Zacks Investment Research upgraded shares of Solid Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 16th. Finally, Credit Suisse Group began coverage on shares of Solid Biosciences in a research report on Thursday, September 6th. They issued a “neutral” rating and a $38.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $42.56.
SLDB stock opened at $25.69 on Friday. The company has a market capitalization of $1.02 billion and a PE ratio of -8.92. Solid Biosciences Inc has a 12 month low of $6.83 and a 12 month high of $54.84.
Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings results on Tuesday, November 13th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.01. Sell-side analysts predict that Solid Biosciences Inc will post -2.21 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/12/08/trexquant-investment-lp-takes-341000-position-in-solid-biosciences-inc-sldb.html.
Solid Biosciences Profile
Solid Biosciences Inc engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation.
Read More: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.